Trovagene reports on drug targeting Non-Hodgkin Lymphoma cell lines
Trovagene Inc., a precision medicine biotechnology company, recently announced positive results from preclinical research of PCM-075 with a Histone deacetylase inhibitor in Non-Hodgkin Lymphoma cell lines. Read More »